Log In
BCIQ
Print this Print this
 

CVac

Also known as: Mannan/MUC-1 vaccine

  Manage Alerts
Collapse Summary General Information
Company Prima BioMed Ltd.
DescriptionEx vivo cancer vaccine using a patient's own dendritic cells primed with the tumor antigen mucin 1 (MUC1; CD227) and a mannan-fusion protein (M-FP)
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationOvarian cancer
Indication DetailsMaintenance treatment of epithelial ovarian, primary peritoneal or fallopian tube cancer patients in complete remission; Maintenance treatment of ovarian cancer; Treat ovarian cancer; Treat ovarian cancer in patients in first or second remission
Regulatory Designation U.S. - Fast Track (Treat ovarian cancer);
U.S. - Orphan Drug (Treat ovarian cancer);
EU - Orphan Drug (Treat ovarian cancer)
PartnerNeopharm Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/18/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today